Drug Profile
PF 4634817
Alternative Names: PF-04634817; PF-46334817; PF4634817Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Diabetic nephropathies; Hepatic fibrosis
Most Recent Events
- 08 Oct 2015 Pfizer terminates a phase II trial in Diabetic macular oedema in USA, Bulgaria, Czech Republic, Hungary, Germany, Israel, Poland, Romania and Moldova (NCT01994291; EudraCT2013-003147-27)
- 10 Sep 2014 Phase-II clinical trials in Diabetic macular oedema in Moldova (PO)
- 01 Sep 2014 Pfizer completes a phase II trial in Diabetic nephropathies in Argentina, Australia, Canada, Germany, Hong Kong, Italy, Malaysia, Peru, Poland, Puerto Rico, Romania, South Korea, Spain and USA (NCT01712061; EudraCT2012-003332-23)